Aktiespot

Veracyte, Inc. (Veracyte Inc. R) Aktie

12V.F

€42.98+2.45 (+6.04%)
Chart wird geladen...

Veracyte Inc. R

Eröffnung41.17
Hoch42.98
Tief41.17
Volumen26
P/E46.22
Marktkapitalisierung3.43B
52-Wochen-Hoch42.98
52-Wochen-Tief19.50
Durchschn. Volumen18
DividendeN/A
Beta1.88
EPS0.93

Über Veracyte, Inc. (Veracyte Inc. R) Aktie

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Unternehmensinformationen

Börse: Frankfurt (FRA)
Sektor: Sundhed
Branche: Diagnostik og forskning
Adresse:
6000 Shoreline Court
94080 South San Francisco, United States
Telefon: + 650 243 6300

Analystenempfehlungen

Diese Übersicht gibt einen schnellen Einblick, wie Analysten das Aktienpotenzial basierend auf ihren neuesten Analysen und Kurszielen bewerten.

Niedrigstes Kursziel
Durchschnittliches Kursziel
Median Kursziel
Höchstes Kursziel

Andere sehen auch: